DaxibotulinumtoxinA

Domestic botulinum toxin companies, including Hugel and Daewoong Pharmaceutical, are expanding into the U.S. market. Hugel aims to launch Retivo in the U.S. this year, targeting a 10% market share within three years. The U.S. Botox market, valued at $4.74 billion, is 30 times larger than Korea's, and AbbVie's dominance is declining. Daewoong's Jubo, already in the U.S., saw sales rise to $202 million. Medytox is also preparing to re-enter the U.S. market.

A study by Hema Mistry, PhD, found no evidence that CGRP monoclonal antibodies are more effective than topiramate or Botox for chronic migraine, suggesting they may not be recommended over topiramate without significant price reduction. The review included 11 RCTs testing 6 drugs, showing CGRP antibodies reduced headache days by 2.0-2.5 days/month, with eptinezumab 300 mg and fremanezumab monthly being most effective. Despite higher costs, injected drugs were deemed cost-effective, with topiramate being the least expensive but least effective. Future research priorities include comparing CGRP antibodies and Botox, candesartan vs placebo, and flunarizine vs placebo.

Hugel's Letybo, a botulinum toxin product, received FDA approval, making it the second Korean company to enter the U.S. market. Expected annual sales and operating profit for Hugel are 377.2 billion won and 153.7 billion won, respectively, with a 58% overseas sales ratio. Letybo is now available in 64 countries, with significant growth in China and recent launch in Indonesia. Hugel faces a final ruling on a trade secret infringement lawsuit with Medytox on Oct. 10.

Sihuan Pharmaceutical Holdings Group Ltd. announced a new program to buy back up to HK$500 million of its shares over 12 months, supported by a strong portfolio of innovative drugs and diabetes biosimilars. The company, originally focused on cardiovascular and oncology generic drugs, expanded into medical aesthetics in 2021. Despite a 10% revenue drop in H1 2024, medical aesthetics revenue surged 66.4%. Shares surged 23.6% to a 52-week high.

Galderma Korea appoints Lee Jai-hyuck, former aesthetics business unit director, as new GM. Lee, with over 25 years in global pharmaceutical and aesthetics industries, succeeds Kim Youn-hee. He led successful product launches and brand renewals, enhancing the company's portfolio and growth.

Motley Fool contributors recommend AbbVie, Amgen, and Pfizer as top dividend stocks for October, highlighting their strong dividend histories, yields, and business strengths.

New Kids on the Block highlights September's best product launches, including SkinMedica's HA⁵ Hydra Collagen Replenish + Restore Hydrator, Garage Clothing's loungewear, Caliray's Blurry Blush, Tecovas' Dakota boots, Nars' Explicit Lipstick, Quince's cashmere sweaters, Beachwaver's Heatless Curl Kit, Heat Healer's lymphatic leggings, and Typology Paris' Fortifying Brow Gel.

ResMed sees GLP-1 drugs boosting CPAP sales; Ron Renaud returns to biotech with Kailera Therapeutics; Gilead licenses lenacapavir for generic production in low-income countries; Senators urge FTC to investigate PBMs over private-label deals; dockworker strike threatens GLP-1 drug supplies; Hurricane Helene impacts Baxter's supply network.

QR678 appoints medtech leader Sridhar Ranganathan to advisory board, leveraging his expertise in biotechnology, healthcare, and aesthetics to bolster strategic direction and market penetration.